Blake Martell

Cooley advised Inscripta, a global leader in genome engineering technology, on its acquisition of Infinome Biosciences and Sestina Bio. These acquisitions advance Inscripta’s strategy to develop and commercialize biomanufactured products for a broad spectrum of industrial and consumer markets. They also demonstrate Inscripta’s confidence in the commercial potential of the bioeconomy and the power of genome engineering to accelerate biomanufacturing innovation. Partner Mike Nelson led the Cooley team.

Cooley advised ViaCyte, a biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for Type 1 diabetes (T1D), on its definitive agreement to be acquired by global biotechnology company Vertex Pharmaceuticals for $320 million in cash. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team advising ViaCyte.

Cooley advised Abnormal Security, a leading artificial intelligence-based cloud-native email security platform, on its $210 million Series C financing round, which brings the company’s valuation to $4 billion. Lawyers Josh Seidenfeld, Nan Yang, Rachel Lydon and Kaavya Gowda led the Cooley team advising Abnormal Security.

Cooley advised 2C2P, a global payments platform, on its strategic partnership with Ant Group, an innovative technology provider that strives to bring the world inclusive, green and sustainable services. Lawyers Matthew Bartus and Gwenlynne Lee led the Cooley team advising 2C2P.

Cooley advised financial-services mobile app ONE Finance on its completed acquisition by Hazel, an independent fintech launched in partnership with Walmart and investment firm Ribbit Capital. Peter Werner and Luke Blackett led the Cooley team advising ONE.